Lowest-Rated StocksLowest-RatedNASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free DOCS Stock Alerts $23.72 -0.13 (-0.55%) (As of 05/16/2024 ET) Add Compare Share Share Today's Range$23.53▼$23.9650-Day Range$23.00▼$28.5052-Week Range$19.71▼$36.29Volume4.86 million shsAverage Volume1.71 million shsMarket Capitalization$4.43 billionP/E Ratio35.94Dividend YieldN/APrice Target$28.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Doximity alerts: Email Address Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.07 Rating ScoreUpside/Downside21.5% Upside$28.82 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 17 Articles This WeekInsider TradingSelling Shares$67,425 Sold Last QuarterProj. Earnings Growth6.94%From $0.72 to $0.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.38 out of 5 starsMedical Sector311th out of 929 stocksCustom Computer Programming Services Industry11th out of 24 stocks 3.0 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.07, and is based on 2 buy ratings, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageDoximity has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Doximity's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 2.9 News and Social Media Coverage News SentimentDoximity has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Doximity this week, compared to 5 articles on an average week.Search Interest20 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.MarketBeat Follows10 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,425.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Doximity's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 6.94% in the coming year, from $0.72 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 35.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 144.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 35.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 169.91.Price to Earnings Growth RatioDoximity has a PEG Ratio of 2.89. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Doximity's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media“Dollar Will Be Worth NOTHING” -MuskElon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher.Click here to claim your free seat ticket now. About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesMay 16 at 9:11 PM | markets.businessinsider.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 16 at 9:11 PM | theglobeandmail.comDoximity's (NYSE:DOCS) Q1 Sales Top Estimates, Full-Year Guidance RaisedMay 16 at 9:11 PM | msn.comDoximity Stock Jumps 10% On Q4 Earnings: What You Need To KnowMay 16 at 4:45 PM | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 16 at 4:10 PM | finance.yahoo.comDoximity Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMay 16 at 4:01 PM | businesswire.comDoximity Announces Fourth Quarter and Fiscal Year 2024 Financial ResultsMay 16 at 1:58 AM | americanbankingnews.comDoximity, Inc. (NASDAQ:DOCS) Receives Average Rating of "Hold" from AnalystsMay 15 at 8:30 PM | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 15 at 6:55 PM | prnewswire.comDoximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 15 at 5:39 PM | businesswire.comKirby McInerney LLP Reminds Doximity, Inc. (DOCS) Investors of Class Action Filing and Encourages Investors to Contact the FirmMay 15 at 12:45 PM | prnewswire.comIMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmMay 15 at 8:23 AM | finance.yahoo.comDoximity, Inc. (DOCS)May 15 at 8:23 AM | finance.yahoo.comDoximity (DOCS) To Report Earnings Tomorrow: Here Is What To ExpectMay 14 at 6:15 AM | fool.com2 No-Brainer Growth Stocks Down 29% and 22% to Buy Hand Over Fist Right NowMay 12, 2024 | markets.businessinsider.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 11, 2024 | prnewswire.comDOXIMITY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCSMay 9, 2024 | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 9, 2024 | americanbankingnews.comDoximity (DOCS) Scheduled to Post Quarterly Earnings on ThursdayMay 8, 2024 | prnewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 8, 2024 | prnewswire.comDoximity, Inc. (DOCS) Investors: June 17, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPMay 7, 2024 | prnewswire.comDOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitMay 6, 2024 | markets.businessinsider.comIMPORTANT DEADLINE ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmMay 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCSMay 5, 2024 | stockhouse.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DOCSMay 5, 2024 | stockhouse.comDOCS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Doximity, Inc. Investors Can Join the Class Action Lawsuit!See More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/16/2024Next Earnings (Confirmed)5/16/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryN/A Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.82 High Stock Price Target$33.00 Low Stock Price Target$23.00 Potential Upside/Downside+21.5%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.66 Trailing P/E Ratio35.94 Forward P/E Ratio32.94 P/E Growth2.89Net Income$112.82 million Net Margins29.39% Pretax Margin37.15% Return on Equity16.08% Return on Assets13.76% Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$468.33 million Price / Sales9.45 Cash Flow$0.74 per share Price / Cash Flow32.00 Book Value$4.98 per share Price / Book4.76Miscellaneous Outstanding Shares186,554,000Free Float113,052,000Market Cap$4.43 billion OptionableNot Optionable Beta1.18 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 51)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 40)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 34)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 56)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 53)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsTransMedics GroupNASDAQ:TMDXNuvalentNASDAQ:NUVLImmunovantNASDAQ:IMVTSelect MedicalNYSE:SEMAlpine Immune SciencesNASDAQ:ALPNView All CompetitorsInsiders & InstitutionsJanus Henderson Group PLCBought 621,590 shares on 5/16/2024Ownership: 1.327%Jacobs Levy Equity Management Inc.Bought 317,379 shares on 5/16/2024Ownership: 0.170%Grandeur Peak Global Advisors LLCSold 107,085 shares on 5/16/2024Ownership: 0.016%Public Employees Retirement Association of ColoradoSold 829 shares on 5/15/2024Ownership: 0.007%LRI Investments LLCBought 1,256 shares on 5/15/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last year. There are currently 1 sell rating, 11 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 14 equities research analysts have issued 1-year target prices for Doximity's shares. Their DOCS share price targets range from $23.00 to $33.00. On average, they predict the company's share price to reach $28.82 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2024? Doximity's stock was trading at $28.04 at the beginning of the year. Since then, DOCS shares have decreased by 15.4% and is now trading at $23.72. View the best growth stocks for 2024 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our DOCS earnings forecast. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) released its quarterly earnings data on Tuesday, November, 9th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.13. The business had revenue of $79.35 million for the quarter, compared to analysts' expectations of $73.60 million. Doximity had a net margin of 29.39% and a trailing twelve-month return on equity of 16.08%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Jacob Forward ETF (JFWD), Janus Henderson Small Cap Growth Alpha ETF (JSML), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and Natixis U.S. Equity Opportunities ETF (EQOP). What guidance has Doximity issued on next quarter's earnings? Doximity updated its first quarter 2025 earnings guidance on Thursday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $119.5 million-$120.5 million, compared to the consensus revenue estimate of $119.2 million. When did Doximity IPO? Doximity (DOCS) raised $501 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 23,300,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.77%), Baillie Gifford & Co. (3.33%), William Blair Investment Management LLC (2.96%), Clearbridge Investments LLC (2.93%), Janus Henderson Group PLC (1.33%) and Edmond DE Rothschild Holding S.A. (1.06%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden FINISHED On June 13th?Paradigm PressThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe #1 Investment of the Decade… Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityWhy Is Gold On a MASSIVE rally? Huge AlertsUrgent Nvidia WarningAltimetryThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.